Cancer Center Amsterdam
-
Publisher Correction: BIRC2–BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia (Scientific Reports, (2022), 12, 1, (45), 10.1038/s41598-021-04042-9)
Roohollahi, K., de Jong, Y., Pai, G., Zaini, M. A., de Lint, K., Sie, D., Rooimans, M. A., Rockx, D., Hoskins, E. E., Ameziane, N., Wolthuis, R., Joenje, H., Wells, S. I. & Dorsman, J., Dec 2022, In: Scientific reports. 12, 1, 5768.Research output: Contribution to journal › Comment/Letter to the editor › Academic
-
BIRC2–BIRC3 amplification: a potentially druggable feature of a subset of head and neck cancers in patients with Fanconi anemia
Roohollahi, K., de Jong, Y., Pai, G., Zaini, M. A., de Lint, K., Sie, D., Rooimans, M. A., Rockx, D., Hoskins, E. E., Ameziane, N., Wolthuis, R., Joenje, H., Wells, S. I. & Dorsman, J., 7 Jan 2022, In: Scientific reports. 12, 1, p. 45 45.Research output: Contribution to journal › Article › Academic › peer-review
-
A "late-but-fitter revertant cell" explains the high frequency of revertant mosaicism in epidermolysis bullosa
van den Akker, P. C., Pasmooij, A. M. G., Joenje, H., Hofstra, R. M. W., te Meerman, G. J. & Jonkman, M. F., 2018, In: PLOS ONE. 13, 2, e0192994.Research output: Contribution to journal › Article › Academic › peer-review
- All publications